Abstract LB200: Simultaneous multi-omic analysis of plasma samples from prostate cancer patients to quantify inflammation markers and total circulating cell-free DNA

Abstract Recent interest in non-invasive biopsy methods has led to many studies focusing on circulating, cell-free nucleic acids (ccfNAs) as a biomarker for cancer diagnosis, prognosis, and treatment response monitoring. Elucidation of profiles and trends in ccfNA corresponding to pathologies and treatment states is likely to be significantly enhanced through the simultaneous quantification of protein biomarkers, however current technological limitations require these determinations to be done through separate workstreams, introducing larger sample requirements, disparate sample processing and analysis mechanisms, along with additional equipment and costs and resources. The resulting data from these disparate methods must then be collated, requiring additional time and resources. We present here a novel, microfluidic-based detection technology that can quantify nucleic acid targets alongside protein biomarkers from a single sample using robust PCR amplification. In addition, this novel technology combines traditional qPCR and digital detection modalities within a single, fully automated run to cover a very wide dynamic range without requiring sample dilution, preserving precious samples in an unmanipulated state. This dynamic range capability is particularly useful to address potentially large changes in analyte concentration between healthy and disease state samples. Using Codetta’s Bio Concerto and their Platform technology, we analyzed plasma samples from prostate cancer samples for concentrations of three cytokines important to prostate cancer (IL-6, IL-7, and VEGF), as well as prostate-specific antigen (PSA) and two ccfDNA targets (MT-CO3 mitochondrial DNA and KRAS nuclear DNA) to quantify the concentration of ccfDNA in the samples. Healthy patient samples were analyzed in addition to disease state samples, and data is presented over a time course of patient treatment. Citation Format: William H. Henley, Nathan A. Siegfried, Aashish Srivastava, Joe Gaiteri, Deepak Kumar. Simultaneous multi-omic analysis of plasma samples from prostate cancer patients to quantify inflammation markers and total circulating cell-free DNA [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB200.